Summary of NewLake Capital Partners Update Call Company Overview - **Company Name**: NewLake Capital Partners (OTCPK:NLCP) - **Business Model**: Sale-leaseback REIT focused on cannabis real estate - **Market Position**: Second largest owner of cannabis real estate in the U.S. with 34 properties across 12 states - **Lease Structure**: Average remaining lease term of 12 years and a yield of approximately 13% on leased portfolio [5][6] Financial Performance - **Dividend Growth**: 80% growth in dividends since IPO in mid-2021, although growth has leveled off due to market conditions [7][8] - **Tenant Composition**: Top three tenants (Curaleaf, Cresco, Trulieve) account for about 50% of annualized base rent [7] - **Comparison with Non-Cannabis REITs**: Non-cannabis REITs have lower yields (6%-7%) compared to NewLake's 13% [10][12] Market Dynamics - **Cannabis Sector Sentiment**: The sentiment in the cannabis sector has softened, impacting deal-making and growth strategies [8] - **Comparison with Other Financing Options**: Sale-leaseback REITs provide longer duration and potentially higher proceeds compared to BDCs and mortgage REITs, which typically have shorter transaction durations [14][17] Regulatory Environment - **International Opportunities**: Interest in exploring deals outside the U.S., including Canada and Europe, but regulatory uncertainties remain a concern [22][58] - **Impact of Rescheduling**: Anticipated positive effects from potential rescheduling of cannabis, including increased demand for services and improved credit quality for tenants [60][61] Tenant Issues and Portfolio Management - **Recent Tenant Recoveries**: Properties from Ayr and Rev Clinics have been recovered and are being re-tenanted for cannabis purposes [89][92] - **Proactive Tenant Relationships**: NewLake aims to maintain strong relationships with tenants to maximize returns and address issues collaboratively [95] Investor Considerations - **Dividend Yield**: Attractive low to mid-teens dividend yield, but concerns about discount to NAV and market perception of leverage and dividend sustainability [38][44] - **Market Positioning**: NewLake's focus on a diversified portfolio of cannabis real estate may provide lower volatility compared to direct cannabis operators [36][37] Future Outlook - **Potential for Increased Deal Flow**: Positive regulatory changes could lead to more opportunities in 2026 and 2027, although current activity remains cautious [60][61] - **Challenges Ahead**: The company faces challenges in gaining a listing on major exchanges due to federal cannabis laws, despite potential regulatory changes [79][81]

Core Viewpoint - Canopy Growth has experienced a significant decline in value, losing over 99% in the past five years, and is now considered one of the worst-performing stocks in that period [1] Company Overview - Canopy Growth, once a leading Canadian marijuana company, is currently facing challenges and has shifted focus towards cost-cutting and limiting cash burn [6] - The company has a market capitalization of $500 million, which has garnered attention due to recent news regarding the U.S. rescheduling of marijuana [2] Industry Developments - The U.S. government has rescheduled marijuana from a Schedule I to a Schedule III substance, which will facilitate research and reduce tax burdens for multi-state operators [3][4] - This rescheduling is seen as a potential first step towards broader marijuana legalization, although it does not directly benefit Canopy Growth as a Canadian producer [7] Financial Performance - In the most recent quarter ending September 30, Canopy Growth reported an operating loss of CA$16.9 million (approximately $12.2 million), an improvement from CA$45.9 million in the same quarter the previous year [8] - The company's cash burn rate has decreased significantly, with CA$28.3 million used in the last six months compared to CA$105.6 million in the same period a year ago [8]

Core Viewpoint - Tilray Brands, Inc. is at a pivotal moment as it prepares to report its fiscal Q2 2026 results, with a focus on potential profitability amidst regulatory changes in the cannabis industry [1] Group 1: Financial Performance and Expectations - Investors are closely monitoring the upcoming Q2 earnings release for signs of financial improvement, particularly regarding rescheduling, tax relief, and the new Tilray Medical USA subsidiary [2] - Wall Street anticipates a loss of 20 cents per share and quarterly revenue of $210.95 million, with particular attention on U.S. infrastructure investment and potential tax relief during the Q2 call [6] Group 2: Regulatory Changes and Tax Implications - There is optimism among Tilray investors regarding the DEA's expedited process to reclassify cannabis from Schedule I to Schedule III, which could alleviate the Section 280E tax burden [3] - The shift to Schedule III could fundamentally enhance Tilray's profitability by allowing the company to deduct standard business expenses, potentially unlocking millions in annual cash flow [4] Group 3: Strategic Developments - Tilray launched Tilray Medical USA in late December, aiming to transition from a diversified lifestyle brand to a serious medical pharmaceutical player in the U.S. market [5] - The new subsidiary is expected to leverage Tilray's established European medical infrastructure to dominate the physician-led distribution model mandated by Schedule III [5] Group 4: Cash Position and Strategic Decisions - Investors are considering whether Tilray's substantial cash reserves of $265 million will be used for aggressive mergers and acquisitions or if high interest rates and domestic competition will lead to a more cautious approach [7]

Industry Overview - The cannabis sector has experienced a turnaround in the second half of 2025, with industry leaders like Tilray Brands seeing nearly a 200% increase in share prices over the past six months, indicating potential for continued momentum into 2026 [1] - The cannabis industry has faced dismal performance in recent years, but recent regulatory developments in the U.S. have sparked renewed investor interest [2] Regulatory Changes - President Donald Trump signed an executive order to reclassify marijuana, moving it from Schedule 1 to Schedule 3, which has significant implications for the cannabis industry [3][4] - Schedule 1 drugs are considered the most dangerous with no accepted medical use, while Schedule 3 drugs have lower potential for abuse and some accepted medical uses [3] Implications of Reclassification - The reclassification will facilitate research into potential medical uses for cannabis, improve access to banking services for pot growers, and alter tax implications for cannabis companies [4][5] - Companies in the cannabis sector will be able to deduct normal business expenses from their income, potentially leading to higher operating profits and margins [5] Impact on Tilray - Despite the positive regulatory changes, Tilray's current business model does not generate revenue from marijuana sales in the U.S., as it primarily offers hemp-based products, which are not classified as controlled substances [8] - The recent surge in Tilray's shares is driven by expectations surrounding cannabis reclassification, which has now materialized, but significant challenges remain for the company moving forward [7]

Core Insights - President Trump signed an executive order on December 18, 2025, to expedite the reclassification of marijuana, potentially making it a Schedule III drug, which would facilitate research and access for Medicare and Medicaid recipients [1][3] - The reclassification could lead to increased investment opportunities in the cannabis industry, which has experienced volatility [1][4] Industry Trends - Cannabis use among Americans aged 65 and older has significantly increased, rising from 4.8% in 2021 to 7% in 2023, marking a 46% increase [2] - The demand for cannabis is growing among seniors, particularly those with chronic diseases, indicating a shift in consumer demographics [6] Regulatory Environment - Marijuana is currently classified as a Schedule I substance, alongside drugs like heroin and LSD, but the executive order aims to change this classification to Schedule III, which includes drugs with recognized medical uses [3] - There is a complex legal landscape across states regarding marijuana use, with support for legalization rising from 36% in 2005 to 70% in 2023, reflecting changing consumer sentiment [5]

Group 1: Economic Measures and Policies - President Trump announced a $1,776 "warrior bonus" for 1.45 million active-duty military personnel, funded by an additional $2.6 billion from tariffs, benefiting approximately 1.28 million active and 174,000 reserve service members [2] - Federal employees will receive an unprecedented two additional days off for Christmas, creating a five-day holiday period, with the government closing on December 24 and 26 [3] - Trump signed an executive order to relax marijuana regulations, moving it from Schedule I to Schedule III, which will facilitate more clinical research and FDA reviews [4][6] Group 2: Housing and Drug Pricing Initiatives - Trump promised to unveil a housing reform plan to address the housing affordability crisis, while claiming inflation has "stopped" [7] - Major pharmaceutical companies, including Merck and GSK, agreed to voluntarily lower drug prices in exchange for tariff exemptions and regulatory relief, with Novartis committing to invest $23 billion in the U.S. over five years [7] Group 3: Political Context and Challenges - Trump's policy announcements come amid declining approval ratings, with Ipsos polling showing his support at 39%, and challenges related to rising living costs and the upcoming 2026 midterm elections [1][9] - The unemployment rate rose to 4.6% in November, the highest since October 2021, with approximately 7.83 million unemployed, indicating economic pressures that could impact the Republican party's control in Congress [8][9]

Group 1 - Tilray Brands closed at $12.34, down 4.2%, and has fallen 94% since its IPO in 2018, with trading volume at 66.7 million shares, 514% above its three-month average [1] - The cannabis industry reacted to President Trump's executive order reclassifying marijuana, with the S&P 500 gaining 0.79% and the Nasdaq Composite rising 1.38%, while peers Canopy Growth and Cronos Group fell by 12% and 2% respectively [2] - Following the reclassification of cannabis from Schedule I to Schedule III, Tilray's stock initially rose but ended the day down 4%, indicating a potential "buy the rumor, sell the news" scenario [3][4] Group 2 - The reclassification may not have met investor expectations for broader recreational use, which could have positively impacted Tilray [4] - Despite the recent news, Tilray remains a risky investment as it is barely profitable on an EBITDA basis, although the reclassification should provide some support for the company [4]

Core Viewpoint - President Trump's decision to downgrade marijuana from a Schedule I controlled substance to a Schedule III category acknowledges its medical value but does not fully legalize it [1][3] Group 1: Policy Changes - The new executive order allows for the reimbursement of CBD products for patients, including cancer patients, under federal health insurance starting next year [1][4] - This reclassification is seen as a significant step in recognizing the medical benefits of marijuana and reducing its perceived abuse potential [3][6] Group 2: Political Reactions - The decision has sparked division within the Republican Party, with 18 senators and 26 House members expressing opposition to the reclassification [1][5] - Despite internal resistance, the Trump administration is continuing this policy shift, which aligns with previous efforts by the Biden administration [5][6] Group 3: Market Impact - Following the announcement, marijuana stocks experienced a significant decline, with ETFs like CNBS dropping nearly 16% and MSOS falling 15.77% [1] - Analysts suggest that the market reaction reflects a "buy the rumor, sell the news" mentality, as investors took profits after substantial gains prior to the executive order [1]

Core Viewpoint - The president has signed an executive order to reclassify marijuana from a Schedule I drug to a Schedule III drug, indicating a shift towards less regulation and acknowledging the therapeutic potential of marijuana, particularly for patients with serious illnesses like cancer [1][2]. Industry Impact - The reclassification of marijuana is expected to have significant implications for the cannabis industry, potentially leading to increased investment and market activity as stocks have already begun to move positively in anticipation of this change [2]. Market Reaction - Following the announcement of the reclassification, cannabis stocks have been on the rise for about a week, indicating strong market interest and investor confidence in the sector's future prospects [2].

Core Viewpoint - Cannabis stocks experienced a rally following reports that President Trump is expected to sign an executive order rescheduling marijuana from Schedule I to Schedule III, which could lead to significant financial benefits for the cannabis sector [1]. Group 1: Tax Implications - Section 280E of the tax code currently prevents cannabis businesses from deducting standard business expenses, resulting in effective tax rates often exceeding 70% [2]. - Rescheduling cannabis to Schedule III would alleviate the burden of Section 280E, potentially allowing many cannabis businesses to achieve profitability for the first time [3]. Group 2: Market Reaction - Cannabis stocks were trading on above-average volumes and trending on social media as investors awaited an official statement from President Trump [5]. - Investors can track the sector through the AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) and individual stocks of major companies such as Tilray Brands, Inc. (NASDAQ:TLRY), Canopy Growth Corp. (NASDAQ:CGC), and others [5]. Group 3: Legal Considerations - While rescheduling would ease research restrictions and tax burdens, it does not eliminate federal criminal penalties for recreational use, and marijuana would still remain illegal under federal law [4]. - The conflict between federal law and state laws that have legalized cannabis will continue to exist [4].